

WHAT IS CLAIMED IS:

Claim 1. Use of oleclumab or antigen-binding fragment thereof and durvalumab or antigen-binding fragment thereof in the manufacture of a medicament for treating ~~a tumor~~unresectable, stage III non-small cell lung cancer (NSCLC) in a human patient, wherein the oleclumab or antigen-binding fragment thereof and durvalumab or antigen-binding fragment thereof are to be administered to the patient,

wherein the oleclumab or antigen-binding fragment thereof is to be administered at a dose of 3000 mg every two weeks (Q2W) for two months and then every four weeks (Q4W) and

wherein the durvalumab or antigen-binding fragment thereof is to be administered at a dose of 1500 mg (Q4W).

Claim 2. The use of claim 1, wherein the medicament is to be administered in combination with chemotherapy to the patient.

~~Claim 3. The use of any one of claims 1 or 2, wherein the oleclumab or antigen-binding fragment thereof is to be administered at a dose of 750 mg to 3000 mg.~~

~~Claim 4. The use of claim 3, wherein the oleclumab or antigen-binding fragment thereof is to be administered at a dose of 1500 mg.~~

~~Claim 5. The use of claim 3, wherein the oleclumab or antigen-binding fragment thereof is to be administered at a dose of 2250 mg.~~

~~Claim 6. The use of claim 3, wherein the oleclumab or antigen-binding fragment thereof is to be administered at a dose of 3000 mg.~~

Claim 7. The use of ~~any one of claims 1-3~~claim 1 or claim 2, wherein the oleclumab or antigen-binding fragment thereof is to be administered intravenously.

Claim 8. — The use of any one of claims 1-7, wherein the durvalumab or antigen-binding fragment thereof is administered at a dose of 1500 mg.

Claim 9. — The use of any one of claims 1-8, wherein the durvalumab or antigen-binding fragment thereof is administered every 21 days to every 28 days.

Claim 10. — The use of any one of claims 1-9, wherein the durvalumab or antigen-binding fragment thereof is administered every 28 days.

Claim 11. — The use of any one of claims 1-10, wherein the durvalumab or antigen-binding fragment thereof is administered every 21 days.

Claim 12. — The use of any one of claims 1-11, wherein the chemotherapy comprises at least one of cisplatin, pemetrexed, nab-paclitaxel, carboplatin, gemcitabine, cisplatin, oxaliplatin, leucovorin, 5-fluorouracil, and docetaxel.

Claim 13. — The use of any one of the preceding claims, wherein the tumor is a solid tumor.

Claim 14. — The use of claim 13, wherein the solid tumor is breast cancer, ovarian cancer, head and neck cancer, prostate cancer, bladder cancer, colorectal cancer, non-small cell lung cancer (NSCLC), glioblastoma, renal cell cancer, or pancreatic cancer.

Claim 15. — The use of claim 14, wherein the pancreatic cancer is pancreatic ductal adenocarcinoma.

Claim 16. — The use of claim 14, wherein the tumor is a resectable NSCLC tumor.

Claim 17. — The use of claim 14 or 16, wherein the tumor is an early stage NSCLC tumor.

Claim 18. — The use of claim 14, wherein the tumor is stage IV NSCLC tumor.

Claim 19. — ~~The use of claim 14, wherein the colorectal cancer is metastatic microsatellite-~~
~~stable.~~

Claim 20. — ~~The use of any one of claims 1-14, wherein the tumor has high PD-L1 expression,~~
~~optionally wherein the tumor is a NSCLC tumor.~~